In the PIONEER 1 and 3 phase 3a trials, oral semaglutide reduced HbA1c and body weight in T2DM patients compared to placebo or sitagliptin.

In a subanalysis of the ACCORD BP trial, intensive blood pressure treatment in T2DM patients receiving standard glycemic control was significantly associated with a decreased risk of CV events, including HF hospitalization.

Prof. Wanner summarizes the key lessons from the EMPA-REG OUTCOME trial in patients with pre-existing CKD.

In a phase 2a study, MEDI0382 improved glycemic control and reduced body weight in patients with stable type 2 diabetes who were overweight or obese.

A prespecified analysis of the ODYSSEY OUTCOME trial showed a bigger treatment effect of alirocumab with no adverse effects on measures of glycemia or new onset diabetes in patients with diabetes compared to those with normoglycemia or pre-diabetes.

Maintaining or changing to a healthy lifestyle after diabetes diagnosis is associated with a significantly lower risk CVD incidence and mortality.

A subanalysis of the ORION-1 phase II trial showed that inclisiran reduced LDL-c in high CV risk patients, irrespective of presence of diabetes.

In two trials of the EASE phase III program, the primary endpoint of change in HbA1c after 26 week of empagliflozin in addition to insulin was met in type 1 diabetes patients.

ADA 2018 In the OBSERVE-4D real world study, canagliflozin did not result in increased risk of below-knee amputation in T2DM patients or patients with established CVD.

Prof. Rydén reviews cardiovascular outcome trials with different types of GLP-1 RAs and explains the differences.

ADA 2018 Analysis of ODYSSEY OUTCOMES trial indicates people with diabetes and prior ACS benefit most from the combination of alirocumab and statins, compared to ACS survivors with prediabetes or with normal glucose levels

In type 2 diabetes patients, semaglutide showed greater reductions of HbA1c and weight compared with liraglutide in the PIONEER 4 trial and compared with sitagliptin in the PIONEER 7 trial.